Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 4 1

Status

Terminated 2Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 7Genitourinary 5Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Peripheral Nervous System Diseases 1Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Single Person × Genitourinary × Clear all
NCT07629700 2026-06-05

ENDEAVOR

University of Florence

Phase NA Not yet recruiting
40 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07260435 2025-12-03

Apa/Enza-short

Erasmus Medical Center

Phase 3 Recruiting
400 enrolled
Genitourinary

Prostatic Neoplasms

NCT03921996 2023-03-09

Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer

Swiss Cancer Institute

Phase 3 Terminated
57 enrolled
Genitourinary

Prostatic Neoplasms

NCT03347045 2017-11-20

TPC-RCT

Alberta Health Services, Calgary

Phase NA Unknown
50 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT00352859 2014-12-30

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Bayer

Phase 4 Terminated
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡